Effectiveness of Intravenous Immunoglobulin for Children with Severe COVID-19: a Rapid Review

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Jun 23

PMID 32566562

Citations 18

Authors

Jingyi Zhang

Yinmei Yang

Nan Yang

Yanfang Ma

Qi Zhou

Weiguo Li

Xia Wang

Liping Huang

Xufei Luo

Toshio Fukuoka

Hyeong Sik Ahn

Myeong Soo Lee

Zhengxiu Luo

Yaolong Chen

Enmei Liu

Kehu Yang

Zhou Fu

Affiliations

Soon will be listed here.

Abstract

Background: Intravenous immunoglobulin (IVIG) is usually used as supportive therapy, but the treatment of COVID-19 by IVIG is controversial. This rapid review aims to explore the clinical effectiveness and safety of IVIG in the treatment of children with severe COVID-19.

Methods: We systematically searched the literature on the use of IVIG in patients with COVID-19, severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS), including both adults and children. We assessed the risk of bias and quality of evidence and reported the main findings descriptively.

Results: A total of 1,519 articles were identified by initial literature search, and finally six studies met our inclusion criteria, included one randomized controlled trial (RCT), four case series and one case report involving 198 patients. One case series showed the survival of COVID-19 patients with acute respiratory distress syndrome (ARDS) was not improved by IVIG. One case report showed high-dose IVIG could improve the outcome of COVID-19 adults. Three observational studies showed inconsistent results of the effect of IVIG on SARS patients. One RCT showed that IVIG did not reduce mortality or the incidence of nosocomial infection in adults with severe SARS. The quality of evidence was between low and very low.

Conclusions: The existing evidence is insufficient to support the efficacy or safety of IVIG in the treatment of COVID-19.

Citing Articles

Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study.

Zhai Y, Li H, Xia P, Jiang Y, Tong H, Zhou D J Med Virol. 2024; 96(11):e70017.

PMID: 39494463 PMC: 11600480. DOI: 10.1002/jmv.70017.

Methodology and experiences of rapid advice guideline development for children with COVID-19: responding to the COVID-19 outbreak quickly and efficiently.

Zhou Q, Li Q, Estill J, Wang Q, Wang Z, Shi Q BMC Med Res Methodol. 2022; 22(1):89.

PMID: 35369859 PMC: 8977048. DOI: 10.1186/s12874-022-01545-5.

Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study.

Scarpa R, DellEdera A, Felice C, Buso R, Muscianisi F, Gambier R Front Immunol. 2022; 13:842643.

PMID: 35359947 PMC: 8960988. DOI: 10.3389/fimmu.2022.842643.

Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study.

Chen Y, Xie J, Wu W, Li S, Hu Y, Hu M Front Immunol. 2022; 12:738532.

PMID: 35154067 PMC: 8828477. DOI: 10.3389/fimmu.2021.738532.

Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study.

Ali H, Elshafei M, Saad M, Mitwally H, Al Wraidat M, Aroos A BMC Pulm Med. 2021; 21(1):354.

PMID: 34743710 PMC: 8572690. DOI: 10.1186/s12890-021-01717-x.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Desborough M, Miller J, Thorpe S, Murphy M, Misbah S . Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med. 2013; 24(4):219-26. DOI: 10.1111/tme.12083. View

Hui D . An overview on severe acute respiratory syndrome (SARS). Monaldi Arch Chest Dis. 2005; 63(3):149-57. DOI: 10.4081/monaldi.2005.632. View

Stockman L, Bellamy R, Garner P . SARS: systematic review of treatment effects. PLoS Med. 2006; 3(9):e343. PMC: 1564166. DOI: 10.1371/journal.pmed.0030343. View

Lai C, Shih T, Ko W, Tang H, Hsueh P . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3):105924. PMC: 7127800. DOI: 10.1016/j.ijantimicag.2020.105924. View

Wang X, Yuan J, Zheng Y, Chen J, Bao Y, Wang Y . [Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen]. Zhonghua Er Ke Za Zhi. 2020; 58(0):E008. DOI: 10.3760/cma.j.issn.0578-1310.2020.0008. View

Wang J, Sheng W, Fang C, Chen Y, Wang J, Yu C . Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis. 2004; 10(5):818-24. PMC: 3323212. DOI: 10.3201/eid1005.030640. View

Cao W, Liu X, Bai T, Fan H, Hong K, Song H . High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis. 2020; 7(3):ofaa102. PMC: 7111600. DOI: 10.1093/ofid/ofaa102. View

Chen Z, Fu J, Shu Q, Wang W, Chen Y, Hua C . [Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):139-146. PMC: 8800665. DOI: 10.3785/j.issn.1008-9292.2020.02.01. View

10.

Wu W, Wang J, Liu P, Chen W, Yin S, Jiang S . [Clinical features of 96 patients with severe acute respiratory syndrome from a hospital outbreak]. Zhonghua Nei Ke Za Zhi. 2003; 42(7):453-7. View

11.

Guyatt G, Oxman A, Kunz R, Brozek J, Alonso-Coello P, Rind D . GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011; 64(12):1283-93. DOI: 10.1016/j.jclinepi.2011.01.012. View

12.

Crayne C, Mitchell C, Beukelman T . Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review. Pediatr Rheumatol Online J. 2019; 17(1):77. PMC: 6882052. DOI: 10.1186/s12969-019-0380-z. View

13.

Bjorkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio J . Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006; 90(4):286-93. DOI: 10.1111/j.1423-0410.2006.00764.x. View

14.

Booth C, Stewart T . Severe acute respiratory syndrome and critical care medicine: the Toronto experience. Crit Care Med. 2005; 33(1 Suppl):S53-60. DOI: 10.1097/01.ccm.0000150954.88817.6. View

15.

. A guide to contraindications to childhood vaccinations. Can J Infect Dis. 2007; 11(1):13-4. PMC: 2094739. View

16.

Ferrara G, Zumla A, Maeurer M . Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections. Am J Med. 2012; 125(10):1036.e1-8. DOI: 10.1016/j.amjmed.2012.01.023. View

17.

Guyatt G, Oxman A, Kunz R, Woodcock J, Brozek J, Helfand M . GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol. 2011; 64(12):1303-10. DOI: 10.1016/j.jclinepi.2011.04.014. View

18.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

19.

. [Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children (first interim edition)]. Zhonghua Er Ke Za Zhi. 2020; 58(3):169-174. DOI: 10.3760/cma.j.issn.0578-1310.2020.03.001. View

20.

Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-236. PMC: 7067204. DOI: 10.1080/22221751.2020.1719902. View